Erfolgreich hinzugefügt!
Kursdaten 
Chart
News + Analysen
Fundamental
Unternehmen
Derivate
Aktion
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 0,84 |
| Novartis AG | 0,09 |
| Sandoz Family Foundation | 0,03 |
| Novartis Foundation For Employee Participation | 0,03 |
| Government Pension Fund - Global (the) | 0,02 |
| Vanguard Health Care Fund | 0,01 |
| Vanguard Total International Stock Index Fund | 0,01 |
| Vanguard Developed Markets Index Fund | 0,01 |
| American Funds Europacific Growth Fund | 0,01 |
| American Funds Capital World Growth & Income Fund | 0,01 |
| Capital Income Builder | 0,01 |
| Robeco Capital Gr. Fds. - Bp European Premium Equities | 0,00 |
| Kempen European High Dividend Fund | 0,00 |
| Nn (l) - Global High Dividend | 0,00 |
| Privatdepot 4 | 0,00 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 359.672.692.442.719,00 | 401.051.184.986.789,00 | 403.725.864.989.119,00 | 397.510.840.034.739,00 | 40.581.793.626.553,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 3.732.248.765 | 22.867.845 | 2.533.862.185 | 27.488.696 | 350.580.054 |
| Summe Anlagevermögen | 9.054.635.625 | 99.075.977 | 1.002.466.659 | 999.768.785 | 1.091.320.032 |
| Summe Aktiva | 1.249.673.859 | 132.036.905 | 13.251.882.745 | 129.832.635 | 1.435.778.268 |
Bilanz (in Mio. EUR) - Passiva
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 2.022.972.035 | 21.952.931 | 241.911.627 | 277.001.625 | 31.634.322 |
| Summe Fremdkapital | 545.732.453 | 54.837.783 | 564.033.596 | 574.984.235 | 660.032.532 |
| Summe Eigenkapital | 703.941.406 | 77.199.122 | 7.611.546.785 | 723.342.115 | 775.745.736 |
| Summe Passiva | 1.249.673.859 | 132.036.905 | 13.251.882.745 | 129.832.635 | 1.435.778.268 |
Adresse
| Lichtstrasse 35, 4056 Basel | |
| Telefon | 41.61.324.11.11 |
| Fax | 41.61.324.80.01 |
| Internet | http://www.novartis.com |
Management
|
Ameet Mallik
Head-Global Marketing, Value & Access |
|
Andreas von Planta
Independent Non-Executive Director |
|
Ann Marie Fudge
Independent Non-Executive Director |
|
Bertrand Bodson
Chief Digital Officer |
|
Charles L. Sawyers
Independent Non-Executive Director |
|
Charlie Hough
VP & Global Head-Strategy |
|
Charlotte Pamer-Wieser
Secretary |
|
Dan Bar-Zohar
Global Head-Neuroscience Development |
|
David Lebwohl
SVP & Franchise Global Program Head |
|
Elizabeth Theophille
Chief Technology & Digital Officer |
|
Enrico Cipro Vanni
Vice Chairman |
|
Frans van Houten
Independent Non-Executive Director |
|
Hans Jörg Reinhardt
Independent Non-Executive Chairman |
|
Harry Werner Kirsch
Chief Financial Officer |
|
James E. Bradner
Member-Executive Committee |
|
Janneke van der Kamp
Member Executive Committee |
|
Jeffrey Engelman
Vice President & Global Head-Oncology NIBR |
|
John Tsai
Chief Medical Officer |
|
Klaus Moosmayer
Chief Ethics Risk & Compliance Officer |
|
Lilli Petruzzelli
Global Head-Immuno-Oncology |
|
Mark Levick
Global Head |
|
Mark Never
Head-Cluster Western Europe |
|
Mary Elizabeth Doherty
Independent Non-Executive Director |
|
Mimi Huizinga
VP & Head-Strategic Data |
|
Nancy C. Andrews
Independent Non-Executive Director |
|
Natacha Theytaz
Head-Internal Audit |
|
Patrice Bula
Director |
|
Samir Shah
Global Head-Investor Relations |
|
Samit Hirawat
Head- Global Oncology Development |
|
Shannon Thyme Klinger
Group General Counsel |
|
Srikant T. Madhav Datar
Independent Non-Executive Director |
|
Steffen Lang
Global Head-Technical Operations |
|
Stephen Moran
Global Head-Strategy |
|
Steven Baert
Head-Human Resources |
|
Ton Büchner
Independent Non-Executive Director |
|
Vasant Narasimhan
Chief Executive Officer |
|
William Thomas Winters
Independent Non-Executive Director |
